GenAns Biotechnology Co., Ltd

GenAns Biotechnology is a China-based company specializing in innovative gene therapies targeting central nervous system disorders and ophthalmic diseases, leveraging advanced screening technologies for therapeutic solutions. Founded in 2022, GenAns Biotechnology Co. , Ltd operates out of Beijing, China, focusing on developing advanced gene delivery systems for therapeutic applications. The company has completed four funding rounds and is actively working to enhance its offerings.

The founder's prior experience details are not publicly available. The latest funding round occurred in January 2026, when the company raised an undisclosed amount in a SERIES C funding led by Beijing Capital Science and Technology Development Group Investment Management, alongside contributions from other investors including Biossom Investment Management and Huatai Zijin Investment, with participation from returning investor Tao Capital. GenAns Biotechnology specializes in innovative gene therapies focused on central nervous system (CNS) disorders and ophthalmic diseases. The company implements advanced neurobiological knowledge and high-throughput screening technologies to develop gene delivery systems targeting specific cells and tissues for therapeutic applications.

Their primary offerings include an AAV high-throughput directional evolution screening platform, a functional protein screening platform, and a drug development platform, all aimed at addressing the unmet clinical needs associated with hereditary and neurological diseases. GenAns Biotechnology's revenue generation model is primarily based on partnerships and collaborations with healthcare institutions and research organizations. These strategic alliances facilitate the development of its gene therapies and enable their entry into clinical trials. The agreements typically include milestone payments tied to development progress and potential royalties from commercialized therapies.

Specific pricing structures for their innovative therapeutic services have not been publicly disclosed, ensuring they reflect the value of the technologies involved. In January 2026, GenAns Biotechnology Co. , Ltd plans to utilize the proceeds from its SERIES C funding round to support the launch of new gene therapy products aimed at addressing CNS disorders. The company targets expansion into regions with significant healthcare challenges related to these conditions, although specific markets have yet to be detailed.

Recent funding will assist in advancing their gene delivery systems and drug development services to meet healthcare sector needs.